Mechanics Bank Trust Department Has $3.81 Million Holdings in Abbott Laboratories $ABT

Key Points

• Mechanics Bank Trust Department cut its Abbott Laboratories stake by 19.4% in the second quarter, selling 10,077 shares and retaining 41,933 shares valued at approximately $3.81 million. Institutional investors collectively own 75.18% of the company.
• Abbott reported quarterly earnings of $1.31 per share and revenue of $12.59 billion, surpassing analyst estimates; revenue increased 13% year over year. The company issued 2026 EPS guidance of $5.45–$5.60.
• Abbott declared a quarterly dividend of $0.63, equal to an annualized $2.52 and a 2.4% yield. Analysts maintain a consensus “Moderate Buy” rating with an average price target of $118.17.

Mechanics Bank Trust Department lowered its position in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 19.4% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 41,933 shares of the healthcare product maker's stock after selling 10,077 shares during the period. Mechanics Bank Trust Department's holdings in Abbott Laboratories were worth $3,805,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the company. MidAtlantic Capital Management Inc. acquired a new position in shares of Abbott Laboratories in the fourth quarter valued at approximately $25,000. Cornerstone Financial Management LLC acquired a new stake in Abbott Laboratories during the 4th quarter worth approximately $25,000. Purpose Unlimited Inc. bought a new stake in Abbott Laboratories during the 4th quarter worth approximately $25,000. Portfolio Resources Advisor Group Inc. acquired a new position in Abbott Laboratories in the 4th quarter valued at approximately $26,000. Finally, Abound Financial LLC bought a new position in shares of Abbott Laboratories during the fourth quarter valued at $26,000. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Stock Up 0.2%

Shares of NYSE:ABT opened at $105.68 on Thursday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $137.49. The business's 50 day simple moving average is $94.63 and its two-hundred day simple moving average is $100.07. The firm has a market cap of $182.86 billion, a P/E ratio of 34.20, a PEG ratio of 2.04 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping the consensus estimate of $1.28 by $0.03. The company had revenue of $12.59 billion during the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The firm's revenue for the quarter was up 13.0% on a year-over-year basis. During the same period in the previous year, the firm posted $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, research analysts forecast that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be given a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 annualized dividend and a yield of 2.4%. Abbott Laboratories's payout ratio is currently 81.55%.

Analyst Ratings Changes

Several research analysts recently issued reports on ABT shares. The Goldman Sachs Group lowered their target price on Abbott Laboratories from $121.00 to $113.00 and set a "buy" rating for the company in a research report on Wednesday, May 27th. Barclays decreased their price target on Abbott Laboratories from $144.00 to $143.00 and set an "overweight" rating for the company in a research note on Monday, April 20th. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $130.00 price objective on shares of Abbott Laboratories in a research note on Friday, July 17th. Stifel Nicolaus reduced their target price on Abbott Laboratories from $145.00 to $120.00 and set a "buy" rating on the stock in a report on Friday, April 17th. Finally, Leerink Partners lowered their price target on shares of Abbott Laboratories from $119.00 to $106.00 and set a "market perform" rating for the company in a report on Tuesday, April 21st. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Abbott Laboratories currently has a consensus rating of "Moderate Buy" and an average price target of $118.17.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source